Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FluCAM vs Fludarabine in Relapsed/Refractory B-CLL
NCT00086580Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2004
- Primary completion
- Jun 2010
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of alemtuzumab in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Sanofi. Primary endpoint: Progression-free Survival up to 6 years. Started Jul 2004; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00086580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086580.